Investment analysts at Wedbush started coverage on shares of Immunic (NASDAQ:IMUX – Get Free Report) in a research note issued on Monday, Marketbeat.com reports. The firm set an “outperform” rating and a $45.00 price target on the stock. Wedbush’s price objective indicates a potential upside of 180.20% from the stock’s current price.
A number of other research analysts also recently issued reports on the company. Lifesci Capital upgraded Immunic to a “strong-buy” rating in a report on Monday, May 4th. Wolfe Research initiated coverage on Immunic in a research report on Friday, May 22nd. They set an “outperform” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research note on Friday, May 29th. B. Riley Financial dropped their price target on Immunic from $40.00 to $27.00 and set a “buy” rating for the company in a research note on Friday, May 22nd. Finally, Wall Street Zen raised Immunic from a “sell” rating to a “hold” rating in a report on Saturday. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $47.25.
Get Our Latest Stock Report on Immunic
Immunic Stock Performance
Immunic (NASDAQ:IMUX – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.36. On average, equities research analysts predict that Immunic will post -3.93 EPS for the current fiscal year.
Institutional Trading of Immunic
Several institutional investors have recently made changes to their positions in IMUX. CTC Alternative Strategies Ltd. purchased a new position in shares of Immunic in the 1st quarter worth approximately $27,000. ADAR1 Capital Management LLC purchased a new position in Immunic in the first quarter worth $33,000. Qube Research & Technologies Ltd bought a new position in Immunic in the 3rd quarter valued at $29,000. Two Sigma Investments LP bought a new position in Immunic in the 3rd quarter valued at $52,000. Finally, Virtu Financial LLC purchased a new stake in shares of Immunic during the 3rd quarter valued at $99,000. Institutional investors own 51.82% of the company’s stock.
Immunic Company Profile
Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.
Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.
Further Reading
- Five stocks we like better than Immunic
- 3 Robotics Stocks Under $10: Value, Momentum, or Bet?
- 3 ETFs Built to Protect Your Money if the Bull Market Breaks
- JFrog’s AI Opportunity Could Fuel a Big Leap in Share Price
- Is SiTime the Best AI Stock You’ve Never Heard Of?
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.
